In this segment of the weekly health-care show, analyst David Williamson explains why investors need to have Arena Pharmaceuticals (ARNA +0.00%) on their radar. Watch and find out how a big EU approval decision, DEA scheduling, and the first quarter sales report of competitor Vivus's (VVUS +0.00%) Qsymia could impact the stock in the coming weeks.
Why Arena Pharmaceuticals should be on your radar.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid